Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD
Advertisement


This list is regulary updated by Neurotransmitter.net's Drug Pipeline Expert, JR Becker (jrbecker76@hotmail.com). Shawn Thomas (shawn@neurotransmitter.net) is responsible for additions, editing, and fact-checking. Dr. Louis Sanfilippo, Professor of Clinical Psychiatry at Yale, is also a valued contributor to this groundbreaking and widely appreciated list.

Treatments for Depression and Anxiety

Drug Name Pharmacologic Action Company Indication Developmental Phase Links
Pristig ® (DVS-233 SR, desvenlafaxine) Metabolite of Effexor ® (venlafaxine) Wyeth Depression, anxiety Approved [ClinicalTrials.gov]
Valdoxan (agomelatine, AGO 178) 5-HT2C antagonist, 5-HT2B antagonist, melatonin M1/M2 receptor agonist Servier, Novartis Depression, anxiety, sleep disorders EU: Resubmitted. Decision expected in mid-2008
US: Phase III

[Receptor activity] [Oct 2005 press release] [ClinicalTrials.gov]
Saredutant (SR 48968) NK2 neurokinin receptor antagonist Sanofi-Aventis Depression, anxiety Phase III - submission expected in the second half of 2008 [Effects of SR 48968 on rodents] [ClinicalTrials.gov]
Amibegron, SR 58611 beta-3-adrenoceptor agonist Sanofi-Aventis Depression, anxiety Phase III [ClinicalTrials.gov]
Vilazodone 5-HT1A partial agonist, serotonin reuptake inhibitor Clinical Data Online, Inc. Depression Phase III [January 2007 Press Release] [ClinicalTrials.gov]
Pexacerfont, BMS-562086 CRF1 antagonist Bristol-Myers Squibb Depression, anxiety Phase III [ClinicalTrials.gov]
Lu AA21004 bis-aryl-sulphanyl modulator Lundbeck Depression, anxiety Phase III [ClinicalTrials.gov]
PD-0332334 Alpha2delta calcium channel blocker Pfizer Anxiety Phase III [ClinicalTrials.gov]
LY2216684 Norepinephrine reuptake inhibitor Eli Lilly Depression, ADHD Phase II [ClinicalTrials.gov]
SSR149415 V1B antagonist Sanofi-Aventis Depression, anxiety, hyperphagia Phase II [SSR149415 review] [ClinicalTrials.gov]
GSK 372475 (NS2359) Dopamine, serotonin, and norepinephrine, reuptake inhibitor GSK, NeuroSearch Depression Phase II [ClinicalTrials.gov]
TIK-101 NMDA partial agonist Tikvah Pharmaceuticals Anxiety disorders Phase II

[Tikvah's Info] ClinicalTrials.gov]
GSK 856553 P38 kinase inhibitor GSK Depression Phase II [ClinicalTrials.gov]
DOV 21, 947 Dopamine, serotonin, and norepinephrine, reuptake inhibitor DOV/Merck Depression, ADHD, RLS Phase II [Antidepressant-like actions of DOV 21,947] [ClinicalTrials.gov]
AZD6765 NMDA antagonist AstraZeneca Depression, anxiety Phase II [ClinicalTrials.gov]
SEP-225289 DA/NE/5-HT reuptake inhibitor Sepracor Depression, anxiety Phase II [ClinicalTrials.gov]
JNJ-18038683 E-mail shawn@neurotransmitter.net if you can share details about how this drug works. Johnson & Johnson Depression Phase II [ClinicalTrials.gov]
ORG 34517/34850 GR antagonist Schering-Plough Depression Phase II [ClinicalTrials.gov]
Nemifitide
(INN 00835)		 Pentapeptide analog of melanocyte-inhibiting factor (MIF-1) administered intravenously (mechanism unknown) Tetragenex Depression Phase II [Innapharma's info] [Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression] [MIF-1 may regulate ACTH secretion] [ClinicalTrials.gov]
Vabicaserin (SCA-136) 5-HT2C agonist Wyeth Depression, anxiety Phase II [ClinicalTrials.gov]
Lu AA24530 Mixed serotonin modulator Lundbeck Depression, anxiety Phase II [ClinicalTrials.gov]
Adipiplon (formerly NG2-73) Partial GABA-A receptor agonist that is preferential for alpha3 subunit-containing receptors Neurogen Anxiety, sleep disorders Phase II

[Neurogen's Info] [ClinicalTrials.gov]
YKP-10A, R228060 Phenylalanine derivative with unknown mechanism Johnson & Johnson/SK Pharmaceuticals Depression Phase II [First Phase II Study] [ClinicalTrials.gov]
ONO-2333Ms CRF1 antagonist Ono Pharmaceuticals Depression, anxiety Phase II [ClinicalTrials.gov]
ORG 26576 AMPA receptor modulator Schering-Plough Depression Phase II [ClinicalTrials.gov]
TC-5214 Nonselective Nicotinic acetylcholine receptor antagonist Targacept Depression Phase II [ClinicalTrials.gov]
TGWOOAD/AA 5-HT1A agonist, 5-HT2 antagonist Fabre-Kramer Anxiety Phase II [Fabre-Kramer's info] [ClinicalTrials.gov]
TGBA01AD Serotonin reuptake inhibitor, 5-HT2 agonist, 5-HT1A agonist, and 5-HT1D agonist Fabre-Kramer Depression Phase II [Fabre-Kramer's info] [ClinicalTrials.gov]
GW823296 (orvepitant) NK1 antagonist GSK Depression, anxiety Phase I [ClinicalTrials.gov]
Tyrima™ Reversible monoamine oxidase A (MAO-A) inhibitor CeNeRx Depression, anxiety Phase I [ClinicalTrials.gov]
PRE703 MgluR agonist Prescient Anxiety Phase I [ClinicalTrials.gov]
Delucemine, NPS 1506 NMDA antagonist NPS Depression, stroke Phase I

[NPS-1506 provides neuroprotection][ClinicalTrials.gov]

Lu AA34893 E-mail shawn@neurotransmitter.net if you can share details about how this drug works. Lundbeck Bipolar depression, anxiety Phase I [ClinicalTrials.gov]
AFQ056 mGluR5 receptor antagonist Novartis Anxiety Phase I [ClinicalTrials.gov]
JNJ-19567470, TS-041 CRF1 antagonist Janssen (Johnson & Johnson), Taisho Depression, anxiety Phase I [ClinicalTrials.gov]
SSR 125543 CRF1 antagonist Sanofi-Aventis Depression, anxiety, hyperphagia Phase I [ClinicalTrials.gov]
YKP3089 Undisclosed mechanism of action SK Pharmaceuticals Anxiety Phase I [ClinicalTrials.gov]
GSK 588045 5-HT1 antagonist GSK Depression, anxiety Phase I [ClinicalTrials.gov]
GSK 163090 5-HT1 antagonist GSK Depression, anxiety Phase I [ClinicalTrials.gov]
TC-2216 Nicotinic acetylcholine receptor (alpha4beta2) antagonist Targacept Depression Phase I [ClinicalTrials.gov]
AZD2327 Enkephalinergic modulator AstraZeneca Anxiety Phase I [ClinicalTrials.gov]
R1647 E-mail shawn@neurotransmitter.net if you can share details about how this drug works. Roche Depression, anxiety Phase I [ClinicalTrials.gov]
URB597 FAAH (fatty acid amide hydrolase) inhibitor Schering-Plough Depression Phase I [ClinicalTrials.gov]
AZD7325 GABA receptor partial agonist AstraZeneca Anxiety Phase I [ClinicalTrials.gov]
AZD6280 GABA receptor partial agonist AstraZeneca Anxiety Phase I [ClinicalTrials.gov]
-- CRF1 antagonist Neurogen Depression, anxiety Pre-clinical  
SSR 126374 CRF1 antagonist Sanofi-Aventis Depression, anxiety, hyperphagia Pre-clinical  
SSR 411298 FAAH (fatty acid amide hydrolase) inhibitor Sanofi-Aventis Depression, anxiety, hyperphagia Pre-clinical [ClinicalTrials.gov]
SSR 241586 NK2/NK3 antagonist Sanofi-Aventis Depression, anxiety, IBS, COPD Pre-clinical  
CRF1 antagonist (backup) CRF1 antagonist GSK/Neurocrine Depression, anxiety Pre-clinical  
R1661 E-mail shawn@neurotransmitter.net if you can share details about how this drug works. Roche Anxiety Pre-clinical  
SAR 102279 NK2 receptor antagonist Sanofi-Aventis Depression, anxiety Pre-clinical  
YKP581 Undisclosed mechanism of action SK Pharmaceuticals (J & J) Depression Pre-clinical  
Lu AA44608 Neuropeptide Y receptor antagonist Lundbeck Depression, anxiety Discontinued [ClinicalTrials.gov]
GW876008 CRF1 antagonist Neurocrine/GSK Depression, anxiety, IBS Discontinued [ClinicalTrials.gov]
Casopitant NK1 antagonist GSK Depression, anxiety, emesis Discontinued [ClinicalTrials.gov]
Elzasonan, CP-448,187 5-HT1B and 5-HT1D receptor antagonist Pfizer Depression, anxiety Discontinued [ClinicalTrials.gov]
PRX-00023 5-HT1A agonist, sigma receptor antagonist Epix Depression Discontinued [Compound Profile] [ClinicalTrials.gov]

Treatments for Sleep Disorders

Drug Name Pharmacologic Action Company Indication Developmental Phase Links
Indiplon IR; Indiplon MR GABA-A modulator (at BZ1 sites) Neurocrine Sleep disorders Approvable, FDA requested more data [Neurocrine's info] [ClinicalTrials.gov]
Silenor® (doxepin)

Doxepin is a potent antagonist at histamine H1 and H2 receptors. It may weakly inhibit the reuptake of norepinephrine and serotonin. Doxepin is also an antagonist at alpha-1-adrenoceptors. The drug binds to both serotonin 5-HT2A and 5-HT2C receptors. In addition, it is an antagonist at all subtypes of muscarinic acetylcholine receptors (references provided elsewhere).

 Somaxon Sleep disorders NDA Submitted 1/08

[Somaxon's info] [ClinicalTrials.gov]
Eplivanserin, SR 46349 5-HT2A receptor antagonist Sanofi-Aventis Sleep disorders Phase III - submission expected in the second half of 2008 [ClinicalTrials.gov]
VEC-162 Melatonin receptor agonist Vanda Pharmaceuticals Sleep disorders, depression Phase III [Vanda's info] [ClinicalTrials.gov]
ORG 50081 (esmirtazapine) 5-HT2 antagonist, H1 antagonist, alpha-2-adrenoceptor antagonist Schering-Plough Sleep disorders, hot flashes Phase III [ClinicalTrials.gov]
Volinanserin, M-100907 5-HT2A antagonist Sanofi-Aventis Sleep disorders Phase III

[M-100907 review] [ClinicalTrials.gov]
Almorexant, ACT-078573 Orexen OX1 and OX2 receptor antagonist Actelion Sleep disorders Phase III [Actelion's Web Site] [ClinicalTrials.gov]
Adipiplon, NG2-73 Partial GABA-A receptor agonist that is preferential for alpha3 subunit-containing receptors Neurogen Sleep disorders, anxiety Phase II

[Neurogen's Info] [ClinicalTrials.gov]
APD125 5-HT2A inverse agonist Arena Sleep disorders Phase II [ClinicalTrials.gov]
PD-6735 Melatonin receptor agonist Phase 2 Discovery Sleep Disorders Phase II [ClinicalTrials.gov]
Pimavanserin, ACP-103 Serotonin 5-HT2A receptor inverse agonist, dopamine D2/D3 receptor partial agonist, acetylcholine M1 receptor agonist Acadia Sleep disorders, Parkinson's disease psychosis, schizophrenia co-therapy Phase II [June 07 Press Release] [ClinicalTrials.gov]
PD-200,390 Voltage-gated calcium channel alpha(2)delta subunit modulator Pfizer Sleep disorders Phase II [ClinicalTrials.gov]
LY2624803, HY10275 5-HT2A and histamine H1 receptor antagonist

Eli Lilly, Hypnion

 Depression, ADHD Phase II [ClinicalTrials.gov]
TIK-301, LY156735 Melatonin agonist, 5-HT2B/5-HT2C antagonist Tikvah Pharmaceuticals Sleep disorders Phase II [ClinicalTrials.gov]
AVE 8488 5-HT2A antagonist Sanofi-Aventis Sleep disorders Pre-clinical  

Treatments for Psychosis/Bipolar Disorder

Drug Name Pharmacologic Action Company Indication Developmental Phase Links
Zomaril (iloperidone) Selective DA/NE/5-HT antagonist Vanda Pharmaceuticals Psychosis NDA Submitted [ClinicalTrials.gov]
Asenapine (ORG 5222) 5-HT2 antagonist, D2 partial agonist Schering-Plough Psychosis NDA Submitted [ClinicalTrials.gov]
Corlux ® (AKA mifepristone or RU-486) Glucocorticoid receptor type II (GRII) antagonist, progesterone receptor antagonist Corcept Psychosis, depression Phase III [Corcept's info] [ClinicalTrials.gov]
Pardoprunox, SLV 308 D2 partial agonist, 5-HT1A agonist Solvay Psychosis, Parkinson's disease Phase III [ClinicalTrials.gov]
LIC477D (licarbazepine) Voltage-gated sodium channel inhibitor Novartis Psychosis Phase III [ClinicalTrials.gov]
Pimavanserin, ACP-103 Serotonin 5-HT2A receptor inverse agonist, dopamine D2/D3 receptor partial agonist, acetylcholine M1 receptor agonist Acadia Antipsychotic-induced side effects, Parkinson's disease psychosis Phase III [June 07 Press Release] [ClinicalTrials.gov]
Ocaperidone D2/5-HT2 antagonist Neuro3d, Janssen Psychosis Phase II

[Drug profile]